| Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial PF Caimi, W Ai, JP Alderuccio, KM Ardeshna, M Hamadani, B Hess, ... The Lancet Oncology 22 (6), 790-800, 2021 | 334 | 2021 |
| Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers AM Evens, A Danilov, D Jagadeesh, A Sperling, SH Kim, R Vaca, C Wei, ... Blood, The Journal of the American Society of Hematology 137 (3), 374-386, 2021 | 89 | 2021 |
| Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution JP Alderuccio, W Zhao, A Desai, N Gallastegui, J Ramdial, E Kimble, ... Journal of clinical oncology 36 (34), 3370-3380, 2018 | 63 | 2018 |
| Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma BT Hill, L Nastoupil, AM Winter, MR Becnel, JR Cerhan, TM Habermann, ... British journal of haematology 184 (4), 524-535, 2019 | 44 | 2019 |
| Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma JP Alderuccio, A Desai, MM Yepes, JR Chapman, F Vega, IS Lossos Clinical case reports 6 (4), 634, 2018 | 36 | 2018 |
| HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis JP Alderuccio, AJ Olszewski, AM Evens, GP Collins, AV Danilov, M Bower, ... Blood advances 5 (14), 2852-2862, 2021 | 33 | 2021 |
| Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation JP Alderuccio, W Zhao, A Desai, J Ramdial, N Gallastegui, E Kimble, ... American journal of hematology 94 (5), 585-596, 2019 | 31 | 2019 |
| Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study AS Zayac, AM Evens, A Danilov, SD Smith, D Jagadeesh, LA Leslie, ... Haematologica 106 (7), 1932, 2021 | 28 | 2021 |
| Efficacy and safety of loncastuximab tesirine (ADCT-402) in relapsed/refractory diffuse large B-cell lymphoma PF Caimi, WZ Ai, JP Alderuccio, KM Ardeshna, M Hamadani, BT Hess, ... Blood 136, 35-37, 2020 | 22 | 2020 |
| Rapid complete response to blinatumomab as a successful bridge to allogeneic stem cell transplantation in a case of refractory Richter syndrome JP Alderuccio, N Mackrides, JR Chapman, F Vega, IS Lossos Leukemia & lymphoma 60 (1), 230-233, 2019 | 22 | 2019 |
| Bilateral radiation therapy followed by methotrexate‐based chemotherapy for primary vitreoretinal lymphoma MI de la Fuente, JP Alderuccio, IM Reis, A Omuro, A Markoe, ... American journal of hematology 94 (4), 455-460, 2019 | 20 | 2019 |
| Survival analysis in treated plasmablastic lymphoma patients: a population‐based study JA Florindez, JP Alderuccio, IM Reis, IS Lossos American journal of hematology 95 (11), 1344-1351, 2020 | 19 | 2020 |
| Granulomatous tattoo reaction in a young man JR Guerra, JP Alderuccio, J Sandhu, S Chaudhari The Lancet 382 (9888), 284, 2013 | 19 | 2013 |
| An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma JP Alderuccio, L Arcaini, MP Watkins, AW Beaven, G Shouse, N Epperla, ... Blood advances 6 (7), 2035-2044, 2022 | 18 | 2022 |
| EBV‐positive HIV‐associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features JR Chapman, AC Bouska, W Zhang, JP Alderuccio, IS Lossos, ... British journal of haematology 194 (5), 870-878, 2021 | 17 | 2021 |
| Splenic marginal zone lymphoma: A US population‐based survival analysis (1999‐2016) JA Florindez, JP Alderuccio, IM Reis, IS Lossos Cancer 126 (21), 4706-4716, 2020 | 15 | 2020 |
| Outcomes of patients with newly-diagnosed Burkitt lymphoma (BL) and central nervous system (CNS) involvement treated in the modern era: A multi-institutional real-world analysis A Zayac, AM Evens, A Stadnik, SD Smith, D Jagadeesh, LA Leslie, C Wei, ... Blood 134, 402, 2019 | 14 | 2019 |
| Revised MALT‐IPI: A new predictive model that identifies high‐risk patients with extranodal marginal zone lymphoma JP Alderuccio, IM Reis, TM Habermann, BK Link, C Thieblemont, ... American journal of hematology 97 (12), 1529-1537, 2022 | 13 | 2022 |
| Duration of response to loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma by demographic and clinical characteristics: subgroup analyses from LOTIS 2 P Caimi, WZ Ai, JP Alderuccio, K Ardeshna, M Hamadani, BT Hess, ... J Clin Oncol 39 (suppl 15), 7546, 2021 | 13 | 2021 |
| Prognostic factors and risk of transformation in marginal zone lymphoma JP Alderuccio, IS Lossos Annals of Lymphoma 4, 2020 | 13 | 2020 |
